

Announcement

Dr. Daniel Steinberg, Pioneer in describing how cholesterol forms, receives Bristol-Myers Squibb Award for Cardiovascular Research

Daniel Steinberg, M.D., Ph.D., whose oxidative modification hypothesis first described how cholesterol forms blockage in the artery walls, is the winner of the Fifth Annual Bristol-Myers Squibb Award for Distinguished Achievement in Cardiovascular Research.

Dr. Steinberg is professor of medicine and co-director of the Specialized Center of Research on Arteriosclerosis (National Heart, Lung and Blood Institute) at the University of California at San Diego. He and his colleagues, Thomas E. Carew and Dawn Schwenke, later proved this theory by demonstrating in animals that treatment with anti-oxidants can inhibit the buildup of cholesterol and slow the progression of atherosclerosis. Later this year, the results of a 12-year study at the Harvard School of Public Health, involving more than 20 000 participants, are expected to confirm those findings in humans.

Dr. Steinberg received the \$50 000 Bristol-Myers Squibb award at a dinner in New York City on May 24. 'Daniel Steinberg's pioneering research on lipids, lipoproteins and atherosclerosis has opened up new avenues towards prevention of coronary artery disease,' said William A. Scott, Ph.D., senior vice president, Exploratory and Drug Discovery Research, Bristol-Myers Squibb Pharmaceutical Research Institute. 'We are proud to honor him as part of our unique program of unrestricted support for cardiovascular research.'

The cardiovascular grants program is one of six biomedical research grants programs funded by the Bristol-Myers Squibb Foundation. The others support research in cancer, infectious disease, the neurosciences, nutrition and orthopaedics. More than \$58 million has been committed to these programs to date.

Bristol-Myers Squibb is a diversified, research-based health and personal care company whose principal businesses are pharmaceuticals, consumer products, nutritionals and medical devices. The company is a world leader in cardiovascular medications, with products such as Capoten, Pravachol, Monopril and Questran.